- Home
- ALHC vs INDV Comparison
ALHC vs INDV Comparison
Compare ALHC & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALHC | INDV |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.7B |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ALHC | INDV |
|---|---|---|
| Price | $21.43 | $32.56 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $23.13 | N/A |
| AVG Volume (30 Days) | ★ 3.0M | 1.8M |
| Earning Date | 04-30-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 100.00 | ★ 8100.00 |
| EPS | N/A | ★ 1.64 |
| Revenue | ★ $3,948,719,000.00 | $1,239,000,000.00 |
| Revenue This Year | $33.69 | N/A |
| Revenue Next Year | $24.74 | N/A |
| P/E Ratio | $405.00 | ★ $19.95 |
| Revenue Growth | ★ 46.06 | 4.29 |
| 52 Week Low | $11.63 | $8.69 |
| 52 Week High | $23.87 | $38.00 |
Technical Indicators
Market Signals| Indicator | ALHC | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 64.20 | 54.69 |
| Support Level | $19.93 | $31.70 |
| Resistance Level | $23.31 | $35.75 |
| Average True Range (ATR) | 0.88 | 1.25 |
| MACD | 0.26 | 0.30 |
| Stochastic Oscillator | 79.35 | 74.01 |
Price Performance
Historical ComparisonAbout ALHC Alignment Healthcare Inc.
Alignment Healthcare Inc is a next-generation, consumer-centric platform that is revolutionizing the healthcare experience for seniors through Medicare Advantage plans. These plans are marketed and sold direct-to-consumer, allowing seniors to select the manner in which customers receive healthcare coverage and services on an annual basis. The company combines a technology platform and clinical model for more effective health outcomes.
About INDV Indivior PLC
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).